Form 8-K - Current report:
SEC Accession No. 0001104659-26-038882
Filing Date
2026-04-02
Accepted
2026-04-02 08:08:18
Documents
17
Period of Report
2026-04-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm267111d2_8k.htm   iXBRL 8-K 33035
2 EXHIBIT 1.1 tm267111d2_ex1-1.htm EX-1.1 257126
3 EXHIBIT 5.1 tm267111d2_ex5-1.htm EX-5.1 9173
4 EXHIBIT 99.1 tm267111d2_ex99-1.htm EX-99.1 10276
5 EXHIBIT 99.2 tm267111d2_ex99-2.htm EX-99.2 11882
9 GRAPHIC tm267111d2_ex99-1img01.jpg GRAPHIC 15530
10 GRAPHIC tm267111d2_ex99-2img001.jpg GRAPHIC 4198
  Complete submission text file 0001104659-26-038882.txt   592092

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA cldx-20260401.xsd EX-101.SCH 3047
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20260401_lab.xml EX-101.LAB 34239
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20260401_pre.xml EX-101.PRE 22380
20 EXTRACTED XBRL INSTANCE DOCUMENT tm267111d2_8k_htm.xml XML 3124
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 26830707
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)